Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 56.17% | 95.14% | 82.57% | 65.19% | 53.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.17% | 95.14% | 82.57% | 65.19% | 53.24% |
| Cost of Revenue | 120.33% | 142.71% | 150.26% | 110.86% | 68.72% |
| Gross Profit | 43.86% | 85.83% | 71.56% | 57.52% | 50.59% |
| SG&A Expenses | 13.31% | 22.08% | 28.73% | 24.11% | 34.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.02% | 43.99% | 43.49% | 32.46% | 29.02% |
| Operating Income | 269.32% | 654.86% | 751.92% | 383.56% | 240.70% |
| Income Before Tax | 1,894.75% | 342.90% | 296.75% | 205.47% | 113.37% |
| Income Tax Expenses | -2,373.69% | 86.07% | 110.72% | 109.48% | -776.59% |
| Earnings from Continuing Operations | 2,200.08% | 397.25% | 365.92% | 239.71% | 135.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,200.08% | 397.25% | 365.92% | 239.71% | 135.65% |
| EBIT | 269.32% | 654.86% | 751.92% | 383.56% | 240.70% |
| EBITDA | 221.79% | 952.59% | 1,495.73% | 563.53% | 342.93% |
| EPS Basic | 2,205.33% | 390.41% | 358.82% | 235.47% | 133.74% |
| Normalized Basic EPS | 914.64% | 338.79% | 294.33% | 203.84% | 124.01% |
| EPS Diluted | 2,373.96% | 381.54% | 349.10% | 229.52% | 130.51% |
| Normalized Diluted EPS | 1,085.85% | 329.72% | 286.23% | 199.32% | 119.86% |
| Average Basic Shares Outstanding | 2.24% | 2.35% | 2.55% | 2.63% | 2.72% |
| Average Diluted Shares Outstanding | 4.57% | 6.20% | 5.52% | 4.57% | 3.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |